Press Releases
Results
showing 1-10 of 144
2024 Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy Presented to Advocate who is Raising the Research Profile of Latin America
2024 Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy Presented to Advocate who is Raising the Research
National PrEP Advocates Applaud CDC PrEP Pilot Launch
Advocates applaud the announcement of the five jurisdictions to receive funding as part of a first-of-its-kind Centers of Disease Control and Prevention (CDC) PrEP pilot. The initiative has the potential to show how a National PrEP Program, as championed by advocacy organizations all over the US, could transform equitable PrEP access by greatly simplifying cost coverage, expanding access to providers, and creating more effective and community-driven education and awareness initiatives. PrEP4All, PrEP in Black America, HIVMA, and AVAC stand ready to work alongside key stakeholders in the five jurisdictions chosen—Baltimore, Houston, Florida, Oklahoma, and South Carolina—and provide insights from the last three years of multi-stakeholder discussions led by our organizations.
Prevention Option:
AVAC Calls on Gilead and Global Stakeholders to Accelerate Access to Generic Lenacapavir Following License Agreements
AVAC welcomes Gilead Sciences’ announcement in granting multiple, non-exclusive licenses to generic manufacturers to produce lenacapavir, their investigational twice-a-year injectable for PrEP, while it is still in clinical trials. This reflects longstanding community advocates’ calls to speed up access to PrEP options immediately following regulatory approval.
Prevention Option:
Second Pivotal Trial of Twice-Yearly HIV Prevention Injection Safe and Highly Effective: PURPOSE 2 Trial Among Gay Men, Trans and Nonbinary People
AVAC welcomes the groundbreaking results of the PURPOSE 2 HIV prevention study of twice-yearly injectable lenacapavir for PrEP among 3,200 cisgender men, transgender men, transgender women, and nonbinary individuals who have sex with partners...
Prevention Option:
Heeding Community Advocates’ Calls, CDC Funds PrEP Pilot Program, Allows Funds to Pay for Generic Medications
For media inquiries contact Michael Chancley at Michael@PrEP4All.org Tuesday, August 6th, 2024 – For the first time ever, the U.S. Centers for Disease Control and Prevention will allow for funding to pay for generic PrEP medications as part of...
Prevention Option:
Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective
Adding additional HIV prevention options means more people may find an option that is right for them. Beyond expanded choice, a twice-yearly injection has the potential to transform the way we deliver HIV prevention to people who need and want it most.
Funding for HIV Survives Extreme Cuts Proposed By House Republicans
Final FY24 Bill Includes Calls for HHS/CDC to Increase PrEP Access 21 March 2024 – PrEP4All, AVAC, HIVMA, and the PrEP in Black America coalition celebrate Congress’ decision to both fund domestic HIV programs at the same level as last year...
Prevention Option:
New COMPASS Governance Structure to Accelerate HIV Policy and Advocacy
AVAC and Pangaea Zimbabwe are thrilled to announce Pangaea Zimbabwe's new leadership of COMPASS Africa, a historic milestone in the development of innovative models for power-sharing in coalition and an important step toward decolonizing global...
The Search for an HIV Vaccine Must Continue
New York, 6 December 2023 – Today the PrEPVacc trial team announced at a special session at the International Conference on AIDS and STIs in Africa (ICASA) in Harare, Zimbabwe, that they were stopping vaccinations in the...
Prevention Option:
AVAC Applauds the Selection of Dr. Jeanne Marrazzo as New Director of NIAID
AVAC enthusiastically applauds the selection of Jeanne Marrazzo, MD, to serve as the new director of the NIH’s National Institute of Allergy and infectious Disease (NIAID). Dr. Marrazzo brings unparalleled leadership and research expertise to this pivotal role at NIAID, which oversees some of the largest investments to advance research on HIV and sexually transmitted infections in the world, at such a critical moment in global health science and politics.
Prevention Option:
showing 1-10 of 144